Harvard Bioscience financials
$7.96−0.25%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $22.7M | $20.8M | $23.7M | $20.6M | $20.4M | $21.8M | $24.6M | $22.0M | $23.1M | $24.5M | $28.2M | $25.4M |
| Gross profit | $12.6M | $12.2M | $14.2M | $12.0M | $11.5M | $12.2M | $14.0M | $12.8M | $13.2M | $14.8M | $16.3M | $14.7M |
| Gross margin | 55.6% | 59.0% | 59.7% | 58.4% | 56.4% | 56.0% | 57.1% | 58.1% | 57.2% | 60.3% | 58.0% | 58.1% |
| Operating income | -$978.0K | -$1.2M | $1.7M | $197.0K | -$819.0K | -$49.7M | $11.0K | -$1.9M | -$2.1M | -$2.3M | $282.0K | -$933.0K |
| Net income | -$2.9M | -$3.4M | -$2.8M | -$1.2M | -$2.3M | -$50.3M | $18.0K | -$4.8M | -$2.9M | -$4.7M | -$1.8M | -$1.2M |
| Net margin | −12.8% | −16.5% | −12.0% | −6.0% | −11.2% | −231.2% | 0.1% | −21.9% | −12.7% | −19.1% | −6.5% | −4.9% |
| Diluted EPS | $-0.64 | $-0.77 | $-0.23 | $-0.30 | $-0.52 | $-11.42 | $0.00 | $-1.10 | $-0.70 | $-1.10 | $-0.43 | $-0.30 |
| EBITDA | $397.0K | $176.0K | $3.1M | $1.5M | $797.0K | -$62.0K | $1.8M | -$59.0K | -$268.0K | -$498.0K | $2.1M | $846.0K |
| Operating cash flow | $325.0K | -$662.0K | -$96.0K | $1.1M | $2.8M | $3.0M | $1.7M | -$842.0K | -$846.0K | $1.4M | $4.3M | $4.4M |
| Free cash flow | -$363.0K | -$1.1M | -$545.0K | $877.0K | $2.7M | $2.5M | $1.4M | -$1.7M | -$1.7M | $758.0K | $3.5M | $4.1M |
| Diluted shares | 4.5M | 4.5M | 12.4M | 4.5M | 4.4M | 4.4M | 4.4M | 4.4M | 4.3M | 4.3M | 4.2M | 4.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $6.5M | $7.1M | $8.6M | $6.8M | $7.4M | $5.5M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $36.7M | $36.2M | $35.9M | $34.0M | $34.9M | $36.0M |
| Total assets | $76.3M | $77.9M | $80.1M | $78.0M | $80.1M | $79.8M |
| Total liabilities | $68.9M | $67.9M | $66.3M | $63.9M | $64.4M | $65.0M |
| Shareholders' equity | $7.4M | $10.0M | $13.7M | $14.1M | $15.7M | $14.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology